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Background: Endoscopic lung volume reduction (eLVR) is a therapeutic option for selected 
patients with COPD and severe emphysema. Infectious exacerbations are serious events in these 
vulnerable patients; hence, prophylactic antibiotics are often prescribed postinterventionally. 
However, data on the microbiological airway colonization at the time of eLVR are scarce, and 
there are no evidence-based recommendations regarding a rational antibiotic regimen.
Objective: The aim of this study was to perform a clinical and microbiological analysis of 
COPD patients with advanced emphysema undergoing eLVR with endobronchial valves at a 
single German University hospital, 2012–2017.
Patients and methods: Bronchial aspirates were obtained prior to eLVR and sent for micro-
biological analysis. Antimicrobial susceptibility testing of bacterial isolates was performed, and 
pathogen colonization was retrospectively compared with clinical parameters.
Results: At least one potential pathogen was found in 47% (30/64) of patients. Overall, 
Gram-negative bacteria constituted the most frequently detected pathogens. The single most 
prevalent species were Haemophilus influenzae (9%), Streptococcus pneumoniae (6%), and 
Staphylococcus aureus (6%). No multidrug resistance was observed, and Pseudomonas 
aeruginosa occurred in 5% of samples. Patients without microbiological airway colonization 
showed more severe airflow limitation, hyperinflation, and chronic hypercapnia compared to 
those with detected pathogens.
Conclusion: Microbiological airway colonization was frequent in patients undergoing eLVR 
but not directly associated with poorer functional status. Resistance testing results do not sup-
port the routine use of antipseudomonal antibiotics in these patients.
Keywords: COPD, endoscopic lung volume reduction, emphysema, Haemophilus influenzae, 
Pseudomonas aeruginosa, resistance
Introduction
Patients with advanced COPD and emphysema are often symptomatic despite intensive 
pharmacological treatment. Reducing lung volume in hyperinflated COPD patients is 
an accepted principle to relieve symptoms, as has recently been recommended by the 
Global Initiative for Chronic Obstructive Lung Disease.1 Surgical lung volume reduc-
tion has shown to improve exercise capacity, quality of life, and survival in selected 
patients.2 However, the high burden of comorbidities in COPD increases the risk of 
perioperative morbidity and mortality in this patient population.2,3 Consequently, dif-
ferent endoscopic treatment modalities were developed to reduce the invasiveness of 
this effective approach.4 Endoscopic lung volume reduction (eLVR) has become an 
established treatment for COPD patients with advanced emphysema.1,5 During eLVR, 
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endobronchial valves (EBVs), ie, unidirectional duck-bill 
valves that are designed to induce a complete occlusion and 
consecutive deflation of the target lobe, are implanted.6 While 
the procedure itself is associated with lower morbidity than 
surgery, patients undergoing eLVR are at high risk for postint-
erventional COPD exacerbations.7 To prevent such infectious 
complications, all relevant trials in the field of eLVR with 
endobronchial valves used a prophylactic antibiotic treatment 
regimen. However, the antimicrobial substances used differed 
considerably and included macrolides (eg, azithromycin), 
second- and third-generation cephalosporins (eg, cefuroxime 
and cefotaxime), and fluoroquinolones (eg, levofloxacine).7–10 
A recent “best practice” expert recommendation suggested an 
empiric, peri-interventional treatment with a broad-spectrum 
oral antibiotic but did not further specify which substances 
should be preferably used.11
Few studies have characterized the microbiological air-
way colonization in individuals with advanced lung diseases 
such as COPD patients referred to eLVR treatment or patients 
with lung cancer.12 Indeed, a recent work pertaining to the role 
of the microbial flora in these patients revealed a significant 
microbiological airway colonization but judged that due to 
“the lack of exhaustive microbiological studies, the conclu-
sions that can be reached remain inconclusive”, ie, it remains 
to be elucidated whether the presence of these pathogens 
might give rise to infectious complications.12 Indeed, it is 
widely unknown which microbiological organisms might 
constitute a risk factor if they colonize such patients, and 
there is an ongoing debate whether infectious exacerbations in 
COPD patients might actually be caused by those pathogens 
that previously colonized the patient’s airways. Additionally, 
many COPD patients with advanced emphysema who are 
eligible for eLVR treatment have had several respiratory 
infections during their course of disease and might thus 
have been treated with several antibiotic regimens. It may 
thus be speculated that higher rates of multiresistant Gram-
positive (eg, methicillin-resistant Staphylococcus aureus) 
and particularly Gram-negative pathogens (eg, Pseudomonas 
aeruginosa) can be detected in these patients. Hence, there is a 
need to improve the knowledge on the actual microbiological 
flora in patients undergoing eLVR. Evidence-based recom-
mendations should address 1) whether application of peri-
interventional antibiotic treatment is justified and 2) which 
key pathogens should be covered by such a medication.
Here, we present a single-center study reporting on the 
microbiological airway colonization and antibiotic suscep-
tibility patterns of potential pathogens isolated from COPD 
patients with severe emphysema undergoing eLVR in one 
University hospital in southwest Germany, and we discuss 
the arising implications for the choice of periinterventional 
antibiotic treatment.
Patients and methods
study site and patient selection
This study is a retrospective analysis of consecutive patients 
treated at the Saarland University Medical Center in 
Homburg, Germany, between March 2012 and March 2017. 
All patients who underwent eLVR with endobronchial valve 
implantation were retrieved from an electronic database. The 
procedure was standardized by an institutional protocol dur-
ing the study period. Advanced COPD patients were eligible 
for this treatment modality if they were highly symptomatic, 
despite an established pharmacological combination treat-
ment consisting of long-acting beta agonists, long-acting 
muscarinic antagonists, and inhaled corticosteroids. Fur-
thermore, patients had to quit smoking for at least 3 months 
prior to the intervention. On admission for intervention, acute 
exacerbation or respiratory infection was excluded clinically 
and by laboratory tests. Postinterventionally, all patients 
completed a 5-day course of oral antibiotic treatment (sul-
tamicillin 375 mg twice a day) and 50 mg oral prednisolone. 
The study was approved by the institutional review board of 
Ärztekammer des Saarlandes; No 35/15. The necessity for 
informed consent was waived by the institutional review 
board due to the retrospective nature of the study.
Characteristics of endoscopic and 
periinterventional procedures
Bronchoscopy and periprocedural preparations were per-
formed according to the institutional standard. Pulmonary 
function tests were performed with a Jaeger MasterScreen 
Body System (CareFusion, Rolle, Switzerland); static lung 
volumes were determined by whole-body plethysmography. 
All measurements were performed according to the American 
Thoracic Society (ATS) and the European Respiratory 
Society (ERS) guidelines.13,14 The 6-minute walking test 
(6MWT) was measured in all patients on a 70 m floor after 
providing standard instructions, while supplemental oxygen 
was administered through a nasal cannula as needed to main-
tain the arterial oxygen saturation at 90%.15
Endoscopic interventions were performed under total 
intravenous anesthesia. The patients were intubated and 
mechanically ventilated. Bronchial aspirates were taken 
prior to the intervention and were immediately sent to the 
microbiology laboratory. EBVs (Zephyr EBV; Pulmonx, 
Redwood City, CA, USA) were placed unilaterally in lobar, 
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segmental, or subsegmental bronchi based on the individual 
anatomic conditions with the intention of completely isolat-
ing the target lobe. All patients underwent a chest X-ray 
1 hour after the procedure (or earlier if symptoms occurred) 
to exclude a pneumothorax.
Processing of bronchial aspirates for 
microbiological analysis
Endobronchial aspirates obtained during eLVR were imme-
diately sent via a pneumatic transport system to the micro-
biology laboratory for same-day processing. Gram-stained 
microscope slides were prepared from each specimen, and 
samples were plated on different solid agar media to detect 
bacteria and fungi, ie, blood agar, MacConkey agar, chocolate 
agar, and Sabouraud agar. For the detection of mycobacteria, 
Auramine staining was performed and mycobacterial growth 
indicator tube (MGIT) liquid culture as well as Loewenstein–
Jensen agar and Stonebrink agar were employed. In addition, 
if requested by the clinician, a polymerase chain reaction 
assay for the detection of Bordetella pertussis, Chlamydophila 
pneumoniae, Haemophilus influenzae, Legionella pneumo-
phila, Mycoplasma pneumoniae, and Streptococcus pneu-
moniae was carried out. For the detection of bacteria, fungi, 
and mycobacteria, samples were incubated for 48–72 hours, 
3 weeks, and 12 weeks, respectively, and were regularly exam-
ined for growth. Matrix-assisted laser desorption ionization 
time-of-flight (MALDI-TOF) mass spectrometry was carried 
out for species-specific identification of bacteria and fungi.
antibiotic resistance testing
Culture-grown colonies of bacteria were subjected to auto-
mated antibiotic susceptibility testing using the VITEK2 
system (BioMérieux, Marcy-l’Étoile, France). In case of 
remarkably resistant strains and/or implausible results, 
the Etest method was used on Mueller-Hinton agar to 
determine the specific minimal inhibitory concentrations 
(MICs) of the tested bacterial species. Breakpoints defined 
by the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) were used for interpretation as sensitive, 
intermediately sensitive, and resistant.16
statistical analysis
Statistical analysis was performed using SPSS Version 21 
(IBM Corporation, Armonk NY, USA). Data were ana-
lyzed using Fisher’s exact test or χ2 test, as appropriate, for 
categorical variables and using a two-sided t-test for indepen-
dent samples for continuous variables. A P-value of 0.05 
was considered as statistically significant.
Results
Microbiological airway colonization
Bronchial aspirates stemming from 64 patients were obtained 
during eLVR and sent for microbiological examination. No 
microbial organism was detected in 34 individuals (53%), 
whereas at least one potential pathogen was found in 
30 patients, owing to a bronchial aspirate positivity rate of 
47%. Bacteria accounted for the majority of positive speci-
mens (23/30; 77%), and 14 different species were detected 
in the patient samples, 10 of which were Gram-negative. 
The most prevalent bacteria were H. influenzae (n=6; 9%), 
S. pneumoniae (n=4; 6%), and S. aureus (n=4; 6%). The 
non-fermentative Gram-negative bacterium P. aeruginosa 
was detected in 4.7% of the analyzed samples. Fungi were 
found in 13% of all specimens, and these were mainly yeasts. 
No mycobacteria were found in the cohort. A total of 16% 
of all samples grew more than one organism, but no more 
than three organisms were detected concurrently in one 
sample. Details on the occurrence of bacteria and fungi are 
displayed in Table 1.
Table 1 Microbiological characterization of bacterial and fungal 
lower airway colonization of 64 COPD patients undergoing 
endoscopic lung volume reduction for advanced emphysema in 
homburg, germany, between March 2012 and March 2017
Pathogen Total (n=64)
n %
Total number of positive samples 30a 47
Bacteria 23a 36
gram-positive bacteria 10 16
Staphylococcus aureus 4 6
Streptococcus constellatus 1 2
Streptococcus pneumoniae 4 6
Streptococcus pyogenes 1 2
gram-negative bacteria 17a 27
Achromobacter xylosoxidans 1 2
Bordetella bronchiseptica 1 2
Enterobacter cloacae complex 1 2
Haemophilus influenzae 6 9
Haemophilus parainfluenzae 2 3
Klebsiella pneumoniae 2 3
Moraxella catarrhalis 1 2
Pseudomonas aeruginosa 3 5
Serratia marcescens 2 3
Stenotrophomonas maltophilia 1 2
Fungi 8a 13
Yeasts 6 9
Candida albicans 5 6
Candida glabrate 3 5
Candida krusei 1 2
Molds 2 3
Aspergillus terreus 1 2
Penicillium spp. 1 2
Note: aCocolonization with different organisms was found in some patients.
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Patient characteristics
All 64 patients presented with severe airflow obstruction and 
hyperinflation. The patient characteristics were comparatively 
stratified by individuals with and without detectable micro-
biological airway colonization (Table 2). Those patients with-
out airway colonization showed significantly lower values 
for forced expiratory volume in 1 second (FEV
1
) compared 
to those with the detection of at least one potential pathogen 
(0.62±0.18 versus 0.80±0.37 L, equaling 24.81±7.02 versus 
30.01%±11.35% of predicted). Hyperinflation shown by the 
residual volume-to-total lung capacity (RV/TLC) ratio was 
more pronounced in patients without detection of microbio-
logical growth, ie, 75.97±7.78 versus 70.64±7.92. Of note, 
the noncolonized patients presented also more frequently 
with hypercapnia (44 versus 10%; P=0.002).
antibiotic susceptibility patterns
Among the 10 isolated Gram-positive bacteria strains, resis-
tance to penicillin was observed in one isolate of S. aureus, 
whereas all streptococci were sensitive to penicillin. Three 
S. aureus strains were resistant to macrolides, but all Gram-
positive pathogens were sensitive to ampicillin/sulbactam. 
Among Gram-negative pathogens, all H. influenzae strains 
showed reduced susceptibility to macrolides and two of the 
six strains were resistant to ampicillin/sulbactam, whereas all 
isolates were sensitive to the third-generation cephalosporin 
cefotaxime. One strain of P. aeruginosa displayed resis-
tance to piperacillin/tazobactam, fluoroquinolones, and 
aminoglycosides but remained sensitive to ceftazidime 
and meropenem. Among all Gram-negative bacteria, no 
extended spectrum beta-lactamase-producing species were 
detected and multidrug resistance was not observed. Within 
the Enterobacteriaceae, resistance to ampicillin/sulbactam 
was exclusively observed in two Serratia marcescens strains, 
while all species remained sensitive to piperacillin/tazobac-
tam, cefotaxime, ceftazidime, ciprofloxacin, gentamicin, 
and meropenem. The antimicrobial susceptibility patterns 
of frequently encountered Gram-positive and Gram-negative 
bacteria are summarized in Table 3.
Discussion
In our cohort of patients undergoing eLVR, airway coloniza-
tion with different microbiological organisms was detected 
in half of all individuals. The most prevalent bacteria were 
H. influenzae, S. pneumoniae, and S. aureus. Colonization 
with P. aeruginosa occurred in only 4.7% of all samples. Of 
note, the antimicrobial susceptibility patterns did not yield 
significant rates of multidrug-resistant pathogens, despite 
the patients’ advanced pulmonary impairment and frequent 
previous anti-infective treatment.
COPD exacerbations are defined as an acute worsening 
of respiratory symptoms that requires additional treatment. 
Table 2 Comparison of baseline characteristics in patients undergoing endoscopic lung volume reduction in homburg, germany 
(2012–2017), stratified by microbiological airway colonization
Clinical presentation All patients, N=64 Not colonized, N=34 Colonized, N=30 P-value
age (years) 62.41±8.67 62.28±8.25 62.56±9.26 0.901
Male (n) 32/64 (50) 14/34 (41) 18/30 (60) 0.210
height (m) 1.66±0.10 1.65±0.11 1.67±0.10 0.680
Weight (kg) 62.29±14.88 59.91±13.70 64.99±15.91 0.180
BMI (kg/m2) 22.52±4.50 21.81±4.29 23.32±4.66 0.184
6MWT (m)a 259.37±109.69 248.58±99.44 271.66±120.91 0.419
Blood gas analysis
PaO2 55 mmhg and/or lTO 48/64 (75) 26/34 (76) 22/30 (73) 0.781
PaCO2 50 mmhg 18/64 (28) 15/34 (44) 3/30 (10) 0.002*
Baseline lung function
FeV1 (l) 0.70±0.30 0.62±0.18 0.80±0.37 0.022*
FeV1 (%) 27.25±9.50 24.81±7.02 30.01±11.35 0.035*
VC (l) 2.11±0.87 1.95±0.79 2.29±0.93 0.132
VC (%) 62.72±20.11 59.81±20.37 66.03±19.62 0.219
rV (l) 5.86±1.33 6.09±1.41 5.59±1.20 0.136
rV (%) 271.71±72.04 284.70±59.78 256.98±82.37 0.134
TlC (l) 7.91±1.61 7.99±1.76 7.83±1.46 0.703
TlC (%) 140.09±21.30 143.69±18.87 136.02±23.42 0.158
rV/TlC 73.47±8.23 75.97±7.78 70.64±7.92 0.009*
Notes: Values are presented as n (%) or mean ± sD. *P0.05 was considered statistically significant. a6MWT results were only available for 62 patients.
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in 1 second; lTOT, long-term oxygen therapy; 6MWT, 6-minute walking test; PaCO2, partial pressure 
of carbon dioxide; PaO2, partial pressure of oxygen; rV, residual volume; TlC, total lung capacity; VC, vital capacity.
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These events are of high prognostic relevance and impact 
on the quality of life.1 Especially patients with advanced 
emphysema are prone to exacerbations following bronchos-
copy, even independent of valve placement. Indeed, in the 
BeLieVeR-HIFi trial, Davey et al10 reported that 20 (80%) of 
the 25 patients in the control group developed mild-to-severe 
exacerbations following bronchoscopy with sham valve 
placement. Generally, manifest acute bronchitis, pneumonia, 
and/or lung infections within the first 3 months following 
EBV treatment are reported in up to 20% of individuals who 
underwent eLVR.11 Hence, most interventionists use prophy-
lactic antibiotic and anti-inflammatory treatment to prevent 
postinterventional exacerbations. However, there is no con-
sensus regarding the choice of a rational antibiotic regimen, 
which can mainly be explained by the lack of microbiological 
studies examining the airway colonization of pneumologi-
cal patients who are referred to eLVR treatment.17,18 While 
it is not fully understood whether airway colonization with 
respiratory pathogens increases the risk to develop infections 
caused by the same agents, colonization with multiresistant or 
difficult-to-treat bacteria such as P. aeruginosa is acknowl-
edged to worsen the course of disease.19,20 In addition, recent 
research indicates that chronically colonized COPD patients 
may have a worse clinical course due to the development of 
deleterious immune responses.21 Therefore, it has been rec-
ommended to prescribe “prophylactic” antibiotics at least in 
the subgroup of patients who have had previous colonization 
or infections with pathogenic bacteria.22
In our study, H. influenzae and Gram-positive cocci 
constituted the most frequently encountered pathogen 
species, whereas multidrug resistance was not common. 
P. aeruginosa and other intrinsically resistant Gram-negative 
pathogens such as Achromobacter xylosoxidans and Stenotro-
phomonas maltophilia were rarely encountered. Hence, 
a postinterventional antibiotic treatment with the beta-lactam/
beta-lactamase inhibitor sultamicillin (an oral formulation of 
ampicillin/sulbactam) would have covered virtually 100% 
of Gram-positive pathogens, 75% of Haemophilus spp., and 
many of the remaining Gram-negative bacteria. Of note, the 
second-generation cephalosporin cefuroxime would have 
reached a similar in vitro efficacy. However, macrolide 
antibiotics (ie, erythromycin, clarithromycin, and azithro-
mycin), which are commonly prescribed for respiratory 
infections because of their additional immunomodulatory 
properties,23 would have had significant less activity, which 
can mainly be attributed to the low observed susceptibility 
of H. influenzae and S. aureus to erythromycin. In addition, 
macrolide activity against S. pneumoniae has considerably T
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decreased in Europe, North America, and elsewhere.24,25 
The aforementioned pathogens are of particular relevance 
in COPD patients, in whom they are strikingly prevalent, 
as has recently been confirmed by a study on the etiology 
of community-acquired pneumonia in Germany.26 Indeed, 
H. influenzae is now recognized as one key pathogen that 
induces significant inflammation in the airways of COPD 
patients,27 and it should thus be covered by any antibiotic 
administered to patients undergoing eLVR. While azithro-
mycin has been shown to reduce the frequency of exacer-
bations in patients with COPD,28 its antimicrobial activity 
to effectively clear H. influenzae may be insufficient, and 
long-term treatment with this agent might lead to increased 
macrolide resistance of bacteria colonizing the airways of 
COPD patients.29 Hence, in agreement with the findings 
from our study, the use of a beta-lactam antibiotic might 
be advantageous if compared with macrolides. In addition, 
we did not find high rates of multiresistant Gram-negative 
pathogens, so that the use of antipseudomonal agents would 
not have been advisable.
Interestingly, microbiological airway colonization was 
associated with a better functional status in our study, the 
reason for which remains unclear. Yet, it might be hypoth-
esized that colonized patients were more symptomatic, eg, 
due to recurrent or more frequent exacerbations,30 and might 
thus have sought additional treatment options such as eLVR 
earlier than noncolonized patients. While it has been shown 
repeatedly that some bacterial species (eg, P. aeruginosa) 
negatively impact on COPD patients,16–18 there is insuf-
ficient evidence to conclude that bacterial colonization per 
se worsens the course of the disease. Hence, further studies 
with a larger sample size are warranted to elucidate whether 
a pathogen-specific association between airway colonization 
and clinical signs can be observed.
Our study has limitations that need to be addressed. 
First, the interventional procedures were performed accord-
ing to standardized operating procedures, but the analysis 
was carried out retrospectively and our data stem from a 
limited number of patients treated at a single center, so 
that not all potential confounders (eg, frequency of previ-
ous antibiotic treatment) could be systematically assessed, 
and our results may thus not be uncritically generalized 
to all patients undergoing eLVR. Second, we cannot fully 
exclude that the patients without airway colonization had 
more recently received antibiotic treatment. Yet, it is unlikely 
that anti-infective medication was prescribed at least during 
the last weeks before eLVR, because this procedure was 
exclusively performed in stable COPD patients without an 
active exacerbation. Third, the sensitivity of the employed 
molecular and culture-based diagnostic tests might have been 
further enhanced by the application of additional molecular, 
sequencing-based techniques, which would have allowed a 
more precise characterization of the bronchial microbiome. 
Fourth, obtaining bronchial aspirates is more prone to con-
tamination by upper airway flora than, eg, samples stem-
ming from bronchoalveolar lavages or protected specimen 
brushes. Additional studies are thus warranted to further 
explore the associations between the airway colonization of 
eLVR patients and related infectious complications. Finally, 
it is important to note that in vitro susceptibility profiles do 
not necessarily predict clinical efficacy and should thus be 
interpreted with caution.
Conclusion
Microbiological airway colonization was frequent in patients 
undergoing eLVR. Our findings suggest that postinterven-
tional treatment of these patients with an oral beta-lactam/
beta-lactamase inhibitor (eg, sultamicillin) or a second- 
generation cephalosporin (eg, cefuroxime) would have cov-
ered most pathogens, and these were in vitro more active than 
macrolides. There is an urgent need for additional studies elu-
cidating the clinical significance of microbiological airway 
colonization in COPD patients being treated with eLVR.
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